for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

ImmunoGen, Inc.

IMGN.OQ

Latest Trade

3.31USD

Change

0.18(+5.75%)

Volume

4,770,453

Today's Range

3.13

 - 

3.35

52 Week Range

1.76

 - 

9.83

As of on the NASDAQ ∙ Minimum 15 minute delay

Pricing

Previous Close
3.13
Open
3.13
Volume
4,770,453
3M AVG Volume
48.00
Today's High
3.35
Today's Low
3.13
52 Week High
9.83
52 Week Low
1.76
Shares Out (MIL)
149.88
Market Cap (MIL)
496.12
Forward P/E
-3.54
Dividend (Yield %)
--

Next Event

ImmunoGen Inc to Present Data from Phase 3 FORWARD I Study and Phase 1b FORWARD II Triplet Cohort at ESMO - Conference Call

Latest Developments

More

Immunogen Inc Says Will Not Incur A Loss On Estimated Sub-Lease Arrangement Disclosed On June 27

Immunogen Reports Q2 Loss Per Share $0.29

Immunogen Says Savings Generated By Restructuring Are Expected To Reduce Co's Quarterly Expenses By More Than 50%

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About ImmunoGen, Inc.

ImmunoGen, Inc. is a clinical-stage biotechnology company that develops targeted cancer therapeutics using its antibody-drug conjugate (ADC) technology. An ADC with the Company's technology comprises an antibody that binds to a target found on tumor cells conjugated to one of its anti-cancer agents as a payload to kill the tumor cell once the ADC has bound to its target. Its product candidates include Mirvetuximab soravtansine; IMGN779; IMGN632; and Coltuximab ravtansine. Its portfolio is led by Mirvetuximab soravtansine, a first-in-class ADC targeting folate-receptor alpha (Fra), which is in a Phase III registrational trial called FORWARD I. Its FORWARD II trial consists of cohorts assessing Mirvetuximab soravtansine in combination with Avastin (bevacizumab), Keytruda (pembrolizumab) and carboplatin. The Company has developed tubulin-acting maytansinoid payload agents, which include DM1 and DM4, as well as deoxyribonucleic acid (DNA)-alkylating agents called IGNs.

Industry

Biotechnology & Drugs

Contact Info

830 WINTER ST

+1.781.8950600

http://www.immunogen.com

Executive Leadership

Stephen C. McCluski

Independent Chairman of the Board

Mark J. Enyedy

President, Chief Executive Officer, Director

Richard J. Gregory

Executive Vice President - Research, Chief Scientific Officer

Craig Barrows

Executive Vice President, General Counsel, Secretary

Blaine H. Mckee

Executive Vice President and Chief Business Officer

Key Stats

2.40 mean rating - 10 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2017

0.1K

2018

0.1K

2019(E)

0.0K
EPS (USD)

2017

-0.980

2018

-1.200

2019(E)

-0.954
Price To Earnings (TTM)
--
Price To Sales (TTM)
10.24
Price To Book (MRQ)
--
Price To Cash Flow (TTM)
--
Total Debt To Equity (MRQ)
--
LT Debt To Equity (MRQ)
--
Return on Investment (TTM)
-66.24
Return on Equity (TTM)
-52.58

Latest News

ImmunoGen drug fails cancer study, shares slide 40 percent

U.S. drug developer ImmunoGen Inc said on Friday its experimental ovarian cancer drug failed to meet the main goal of a late-stage study, driving its shares more than 40 percent lower on Friday.

ImmunoGen's ovarian cancer drug fails in late-stage study

U.S. drug developer ImmunoGen Inc said on Friday its experimental ovarian cancer drug failed to meet the main goal of a late-stage study.

BRIEF-ImmunoGen Reports Q1 Loss Per Share $0.30

* IMMUNOGEN REPORTS RECENT PROGRESS AND FIRST QUARTER 2018 OPERATING RESULTS

BRIEF-Immunogen Completes Interim Analysis For Forward I Phase 3 Trial Of Mirvetuximab Soravtansine

* IMMUNOGEN ANNOUNCES SUCCESSFUL COMPLETION OF INTERIM ANALYSIS FOR FORWARD I PHASE 3 TRIAL OF MIRVETUXIMAB SORAVTANSINE IN PLATINUM-RESISTANT OVARIAN CANCER

BRIEF-Immunogen Inc Files For Potential Mixed Shelf Offering

* IMMUNOGEN INC FILES FOR POTENTIAL MIXED SHELF OFFERING; SIZE NOT DISCLOSED - SEC FILING Source text (http://bit.ly/2DablVK) Further company coverage:

BRIEF-Immunogen Inc Reports Qtrly Net Loss Per Common Share, Basic And Diluted Of $0.11

* IMMUNOGEN REPORTS PIPELINE PROGRESS AND 2017 OPERATING RESULTS

BRIEF-Immunogen Says On Jan 8, Co Disclosed It Expects To Report That As Of Dec 31, 2017 It Had Cash And Cash Equivalents Of About $267.1 Mln

* IMMUNOGEN SAYS ON JAN 8, CO DISCLOSED IT EXPECTS TO REPORT THAT AS OF DEC 31, 2017 IT HAD CASH AND CASH EQUIVALENTS OF ABOUT $267.1 MILLION - SEC FILING Source text (http://bit.ly/2CRXR5Q) Further company coverage:

BRIEF-ImmunoGen Announces First Patient Dosed In Phase 1 Study Of IMGN632 For Hematological Malignancies

* IMMUNOGEN ANNOUNCES FIRST PATIENT DOSED IN PHASE 1 STUDY OF IMGN632 FOR HEMATOLOGICAL MALIGNANCIES Source text for Eikon: Further company coverage:

BRIEF-ImmunoGen reports Q3 loss per share $0.61

* ImmunoGen reports recent progress and third quarter 2017 operating results

BRIEF-Immunogen announces investigational new drug application for IMGN632 for hematological malignancies is active

* Immunogen announces investigational new drug application for IMGN632 for hematological malignancies is active

BRIEF-Immunogen prices offering of 14.5 mln common shares at $6.50 per share

* Immunogen announces pricing of public offering of common stock

BRIEF-Immunogen- As of Sept. 30, had cash and cash equivalents of about $194.9 mln

* Immunogen- on Oct, 4,, co disclosed that it expects to report that as of Sept. 30, 2017 it had cash and cash equivalents of about $194.9 million Source: (http://bit.ly/2gcIozK) Further company coverage:

BRIEF-ImmunoGen intends to offer and sell 13 mln shares of common stock​

* ImmunoGen announces proposed public offering of common stock

BRIEF-Immunogen enters privately negotiated exchange agreements

* Immunogen-on Sept 25, co entered privately negotiated exchange agreements with some holders of co's outstanding 4.50% convertible senior notes due 2021

BRIEF-ImmunoGen announces agreements to exchange $76.4 mln of its 4.5 pct convertible senior notes due 2021 for common stock

* ImmunoGen announces agreements to exchange $76.4 million of its 4.50% convertible senior notes due 2021 for common stock

BRIEF-Jazz Pharmaceuticals and Immunogen sign deal to develop, commercialize antibody-drug conjugate products

* Jazz Pharmaceuticals and Immunogen inc announce a strategic collaboration and option agreement to develop and commercialize antibody-drug conjugate products

BRIEF-Jazz Pharmaceuticals and Immunogen announce strategic collaboration and option agreement

* Jazz Pharmaceuticals and Immunogen Inc announce a strategic collaboration and option agreement to develop and commercialize antibody-drug conjugate products Source text for Eikon: Further company coverage:

BRIEF-Polygon Management Ltd reports 5.2 pct passive stake in Immunogen Inc - SEC Filing

* Polygon Management Ltd reports 5.2 percent passive stake in Immunogen Inc, as of August 2, 2017 - SEC Filing Source text: (http://bit.ly/2uAaTff) Further company coverage:

BRIEF-ImmunoGen reports recent progress and second quarter 2017 operating results

* Q2 earnings per share view $-0.16 -- Thomson Reuters I/B/E/S

BRIEF-Immunogen and Sanofi amend license agreements

* Immunogen - co, affiliate of Sanofi have amended their license agreements covering all compounds in development by sanofi using Immunogen's technology

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up